Metagenics, Inc., a nutrigenomics and lifestyle medicine company, has joined the UC San Diego Center for Microbiome Innovation (CMI) as an industry sponsor. The company offers products in the areas of blood sugar balance, body composition, cardiometabolic health, children’s health, gastrointestinal health, general wellness, metabolic detoxification, neurological health, sports nutrition, and stress management; immune men’s and women’s health; and muscle, bone, and joint health.
These glowing avatars (below) are actually maps of molecules. Every day, every inch of skin on your body comes into contact with thousands of molecules — from food, cosmetics, sweat, the microbes that call your skin home. Now researchers can create interactive 3D maps that show where each molecule lingers on your body, thanks to a new method developed by University of California San Diego and European Molecular Biology Laboratory (EMBL) researchers. The technique is published December 21 in Nature Protocols.
Researchers at the University of California San Diego Center for Microbiome Innovation (CMI) have found that sampling the gut microbiome over time can provide insights that are not available with a single time point. The findings could help doctors and researchers more accurately determine if a patient has Crohn's disease. The findings were published as a letter in Gut on October 21, 2017.
Pfizer has joined the UC San Diego Center for Microbiome Innovation as a platinum-level industry sponsor. According to Center director Rob Knight, this relationship aims to build on recent evidence connecting the microbiome to drug response and, together with our other partners in microbiome methods and data science, will potentially help us move from reading out changes in the microbiome to using it to improve patient care. Pfizer will have the opportunity to influence the research directions of the Center by holding two seats on the corporate member board, as well as having regular communication with the center team of experts.
In the Earth Microbiome Project, an extensive global team co-led by researchers at University of California San Diego, Pacific Northwest National Laboratory, University of Chicago and Argonne National Laboratory collected more than 27,000 samples from numerous, diverse environments around the globe. They analyzed the unique collections of microbes — the microbiomes — living in each sample to generate the first reference database of bacteria colonizing the planet. Thanks to newly standardized protocols, original analytical methods and open data-sharing, the project will continue to grow and improve as new data are added.
University of California San Diego researchers have developed the first 3D spatial visualization tool for mapping “’omics” data onto whole organs. The tool helps researchers and clinicians understand the effects of chemicals, such as microbial metabolites and medications, on a diseased organ in the context of microbes that also inhabit the region. The work could advance targeted drug delivery for cystic fibrosis and other conditions where medications are unable to penetrate.
Ants that live in the Amazon rainforest canopy have orders of magnitude more bacteria in their guts than those that live on the ground.
UC San Diego Center for Microbiome Innovation (CMI) researchers and colleagues on the East Coast have for the first time quantified the number of bacteria in the guts of a broad range of ant species in the Amazon rainforest. They found that the primarily herbivorous ants that live in the canopy have orders of magnitude more bacteria than those that live on the ground. The work has implications for the way microbiome studies are conducted. The authors published the study July 27 in Integrative and Comparative Biology.
Researchers at UC San Diego have developed a genome-scale model that can accurately predict how E. coli bacteria respond to temperature changes and genetic mutations. The work sheds light on how cells adapt under environmental stress and has applications in precision medicine, where adaptive cell modeling could provide patient-specific treatments for bacterial infections.
IBM Research and UC San Diego Collaborate to Advance the Use of Artificial Intelligence for Healthy Living.
IBM (NYSE: IBM) and the University of California San Diego have announced a multi-year project to enhance quality of life and independence for aging populations through the new Artificial Intelligence for Healthy Living Center (AIHL), located on the campus of UC San Diego. The groundbreaking center will bring together the technology, artificial intelligence and life sciences knowledge of IBM and UC San Diego to promote critical research and applications in two thematic areas: Healthy Aging and the Human Microbiome.
San Diego, Calif., September 20, 2017 - The second in a series on disruptive technology, Good Bugs v. Bad Bugs was put on by the MIT Enterprise Forum San Diego on September 20, 2017 at Knobbe Martens in San Diego, and featured Rob Knight, professor of pediatrics and computer science and engineering and director of the Center for Microbiome Innovation at UC San Diego, Richard Gallo, MD, Ph.D., chair of the department of dermatology at the UC San Diego School of Medicine and Mark S. Wilson, co-founder and CEO of MatriSys Bioscience, Inc.
The University of California San Diego School of Medicine has entered a five-year strategic partnership with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover meaningful treatments for metabolic diseases.
Center Leadership Member, Rachel Dutton: UC San Diego Biologist Awarded Prestigious Packard Fellowship.
Rachel Dutton, an assistant professor of biology in UC San Diego’s Division of Biological Sciences, will receive a grant of $875,000 over the next five years to pursue her research, which makes use of different kinds of artisanal cheeses as “a simple model system to uncover the inner workings of life within microbial communities.”
Researchers have built drug-delivery capsules that neutralize stomach acid and use the resulting hydrogen peroxide bubbles to propel themselves and deliver an antibiotic. When tested in mice, the micromotors proved slightly more effective than the same dose of antibiotic delivered orally along with an acidity-lowering proton pump inhibitor, researchers report yesterday (August 16) in Nature Communications.
In the not-so-distant future, drug treatments could be delivered straight to the problem area with the help of some very tiny robots. Researchers at the University of California, San Diego successfully treated bacterial gastric infections in mice using micromotors. The use of nanotechnology in medicine is nothing new but this is the first time chemical treatments have been administered in vivo with this kind of technology.
The San Diego Union Tribune
Micromotors thinner than a human hair delivered an antibiotic in the stomachs of mice while neutralizing excess acid, in a study by University of California San Diego scientists. The micromotor-delivered antibiotic reduced populations of H.pylori bacteria, which can cause stomach ulcers. The proof of principle could lead to a safer acid-neutralizing alternative for drug-taking patients than treating them with proton pump inhibitors, which have been linked to various undesirable side effects.
Contacts for the News Media
Deborah L. Jude
Phone: +1 (858) 534-8390